LNAI
What one share of Lunai Bioworks holds
Pharmaceutical Preparations
GEDi Cube B.V. ("GEDi Cube"), acquired on February 13, 2024, filed for bankruptcy and ceased operations. Following GEDi Cube's bankruptcy and subsequent deconsolidation, the Company continued pursuing its AI-driven precision medicine and biomarker discovery strategy through BioSymetrics, which had been acquired prior to the bankruptcy.
Lunai Bioworks’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$1.06 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.57 |
| Cash and investments | $0.37 |
| Debt | $0.08 |
| Book value | −$1.96 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2017 | — | −$1.75 | — | −$0.96 | — | $1.23 |
| 2018 | — | −$2.88 | $0.01 | −$1.99 | — | $43.89 |
| 2019 | — | −$4.80 | $0.19 | −$2.46 | — | $38.23 |
| 2020 | — | −$2.46 | $0.04 | −$2.30 | — | $35.76 |
| 2021 | — | −$5.67 | $0.01 | −$4.38 | — | $33.45 |
| 2022 | — | −$21.59 | $0.00 | −$3.00 | — | $13.70 |
| 2023 | — | −$7.05 | $0.01 | −$2.10 | — | $7.30 |
| 2024 | — | −$9.07 | $0.01 | −$1.13 | — | $8.33 |
| 2025 | — | −$86.27 | — | −$3.82 | — | −$9.63 |
| 2026 | $0.02 | −$1.06 | $0.00 | −$1.57 | — | −$1.96 |